Source: Annual Congress 2012 - COPD treatment and varia
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Pertseva, K. Gashynova (Dnipropetrovsk, Ukraine). Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD. Eur Respir J 2012; 40: Suppl. 56, 3469

Member's Comments

No comment yet.

Related content which might interest you: COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Serum surfactant protein D (SPD) as a specific marker for COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Early stage asymptomatic (HRCT detectable) patients with IPF showed augmented serum surfactant protein D (SP-D) Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Influence of bacterial colonization (BC) on the level of systemic inflammatory markers (SIM) in COPD patients (pts) Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 805s Year: 2006 Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts) Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD Source: International Congress 2014 – Predictors Year: 2014 Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Lymphocyte-to-Monocyte ratio (LMR) and Platelet-to-lymphocyte (PLR) ratio levels as a predictors of lung failure in severe Covid-19 pneumonia patients (pts) Source: Virtual Congress 2021 – COVID - 19: lessons learned Year: 2021